DNV capital
VC Fund
Shenzhen, China
DNV capital is a VC fund in Shenzhen focused on Health Care and Medical Device. DNV Capital concentrates on venture capital investment in start-up period and growth period, the directions of investment cover: medical treatment and health industry, AI, Internet of things, and cloud computing.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries DNV capital invests in
Stages DNV capital invests in
Countries DNV capital invests in
Investment Focus
Industry
- Health Care 2 (29%)
- Medical Device 2 (29%)
- Medical 1 (14%)
- Robotics 1 (14%)
- Therapeutics 1 (14%)
Stage
- Series B 2 (29%)
- Series C 1 (14%)
- Series D 1 (14%)
Country
- China 3 (43%)
- United States 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cyrano Therapeutics
|
Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significantimprovement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program.Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA. | $9M / Series B / Jan 16, 2024 | |
Surgerii Technology
|
Beijing Surrey is a technology company founded by an industry elite active in China's medical equipment. Relying on the core technology of the new generation of flexible continuum robotic arm, running through the implementation paradigm of many types of clinical minimally invasive surgery, and harnessing the powerful system design andintegration capabilities, Beijing Shurui is committed to becoming the first independent independent research and development, production and sales in China. | Series C / Apr 04, 2023 | |
Sanoculis
|
Sanoculis is a medical device start-up company that develops an innovative surgical procedure for the treatment of the Glaucoma. The company offers a new alternative surgical procedure for treating glaucoma. Its Minimally Invasive Micro Sclerostomy (MIMS) solution consists of a single-patient-use sterile tool and a multi-use external machine. Inthe course of the surgery, a sclero-corneal drainage channel is created to reduce intraocular pressure.MIMS is a microfluidic full-thickness procedure developed as an advanced laser sclerotomy. The technique uses a cutting and drilling device to reduce trauma to the surrounding tissue, minimizing scar tissue formation and allowing for a long-lasting filtering bleb. The MIMS channel ensures a controlled fluid flow with minor complications.The company was founded in 2012 and is based in Tel Aviv, Israel | Series C / Jan 25, 2023 | |
Sinovation Medical
|
Sinovation Medical focuses on developing medical robot technology and intelligent medical product innovation. | $43.1M / Series D / Dec 26, 2022 | |
Binhui Biotech
|
Wuhan Binhui Biotechnology Co., Ltd. was established in 2010. The company is located in the Optics Valley Bio City of Donghu National Independent Innovation Demonstration Zone. The company is committed to providing innovative products and services for the field of oncology integration (including diagnosis and treatment), and developing products andservices that have independent intellectual property rights and can compete with other manufacturers on the international stage. | $46.9M / Series B / Apr 19, 2022 | |
XuanZhu Pharma
|
XuanZhu Pharma is an innovative biopharmaceutical company rooted in China, with a global perspective, focusing on tumors, metabolic diseases, infections, and other fields. It has a layout of the entire industry chain from drug discovery, preclinical research, clinical development, and production and sales. | $96.1M / Series B / Dec 31, 2021 | |
Hinova Pharma
|
Hinova Pharma is an innovative drug research and development manufacturer that provides users with compound HC-1119 androgen receptor (AR) antagonism by using drug discovery systems such as medicinal chemistry, biological screening, process research, quality research, clinical reporting, and clinical research. Drugs, HC-1102 androgen receptorinhibitors and other products, for the treatment of advanced prostate cancer and breast cancer. | $147.3M / Series C / Oct 06, 2020 |
Co-Investors
Hongtai Capital Holdings
1 deal together
CCB International
1 deal together
Cowin Venture
1 deal together
Eckuity
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does DNV capital invest in?
DNV capital invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did DNV capital last invest?
The most recent investment recorded for DNV capital closed in Jan 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
